Consistent with prior terms of clearance, FDA is reminded that it will submit an ICR revision if the Medication Guide program is modified in such a way that results in new or different information collection requirements. Any such ICR revisions must be submitted prior to the modifications taking effect.
Inventory as of this Action
Requested
Previously Approved
01/31/2016
36 Months From Approved
01/31/2013
296,719,031
0
296,719,030
16,907,114
0
16,907,110
0
0
0
FDA regulations require the distribution of patient labeling, called Medication Guides, for certain prescription human drugs and biological products used primarily on an outpatient basis that pose a serious and significant public health concern requiring distribution of FDA-approved patient medication information. These Medication Guides inform patients about the most important information they should know about these products in order to use them safely and effectively.
The agency estimate change reflects the correction of a typo on the previous submission.
$0
No
No
No
No
No
Uncollected
Johnny Vilela 301 796-3792 juanmanuel.vilela@fda.hhs.gov
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.